Optimizing Vancomycin Area under the Concentration-Time Curve Targets in Enterococcal Bacteremia: Balancing Efficacy...

Area of Science:

• Pharmacology
• Infectious Diseases
• Clinical Pharmacy

Background:

• Vancomycin is essential for treating enterococcal bacteremia.
• Optimal pharmacokinetic/pharmacodynamic (PK/PD) targets for vancomycin in this context are not well-defined.
• Understanding these targets is crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate the association between vancomycin PK/PD parameters and clinical outcomes in patients with enterococcal bacteremia.
• To identify optimal vancomycin exposure thresholds for efficacy and safety.

Main Methods:

• Retrospective cohort study of 70 patients with enterococcal bacteremia treated with vancomycin.
• Vancomycin area under the concentration-time curve (AUC)/minimal inhibitory concentration (MIC) calculated using Bayesian methods.
• Receiver operating curve (ROC) analysis to determine AUC/MIC thresholds; logistic regression to identify risk factors.

Main Results:

• Unfavorable outcomes occurred in 30% of patients; nephrotoxicity in 14.3%.
• ROC analysis suggested AUC₂₄/MIC thresholds of ≥466.0 for unfavorable outcomes and ≥643.2 for nephrotoxicity.
• Nephrotoxicity and Charlson Comorbidity Index (CCI) were independent risk factors for unfavorable outcomes.

Conclusions:

• Nephrotoxicity and comorbidities are stronger predictors of unfavorable outcomes than vancomycin AUC/MIC ratios.
• Individualized treatment strategies are needed to balance vancomycin efficacy and toxicity.
• Further large-scale studies are required to confirm optimal AUC/MIC thresholds.